GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nymox Pharmaceutical Corp (OTCPK:NYMXF) » Definitions » Cyclically Adjusted Book per Share

Nymox Pharmaceutical (Nymox Pharmaceutical) Cyclically Adjusted Book per Share : $-0.02 (As of Sep. 2023)


View and export this data going back to 1997. Start your Free Trial

What is Nymox Pharmaceutical Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Nymox Pharmaceutical's adjusted book value per share for the three months ended in Sep. 2023 was $-0.020. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $-0.02 for the trailing ten years ended in Sep. 2023.

During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 23.70% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 15.20% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -9.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Nymox Pharmaceutical was 23.70% per year. The lowest was -100.00% per year. And the median was -13.75% per year.

As of today (2024-04-27), Nymox Pharmaceutical's current stock price is $0.30. Nymox Pharmaceutical's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2023 was $-0.02. Nymox Pharmaceutical's Cyclically Adjusted PB Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Nymox Pharmaceutical was 229.33. The lowest was 229.33. And the median was 229.33.


Nymox Pharmaceutical Cyclically Adjusted Book per Share Historical Data

The historical data trend for Nymox Pharmaceutical's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nymox Pharmaceutical Cyclically Adjusted Book per Share Chart

Nymox Pharmaceutical Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.10 -0.09 -0.08 -0.07 -0.04

Nymox Pharmaceutical Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.05 -0.04 -0.03 -0.03 -0.02

Competitive Comparison of Nymox Pharmaceutical's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Nymox Pharmaceutical's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nymox Pharmaceutical's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nymox Pharmaceutical's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Nymox Pharmaceutical's Cyclically Adjusted PB Ratio falls into.



Nymox Pharmaceutical Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Nymox Pharmaceutical's adjusted Book Value per Share data for the three months ended in Sep. 2023 was:

Adj_Book= Book Value per Share /CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-0.02/129.8595*129.8595
=-0.020

Current CPI (Sep. 2023) = 129.8595.

Nymox Pharmaceutical Quarterly Data

Book Value per Share CPI Adj_Book
201312 -0.186 98.326 -0.246
201403 -0.190 99.695 -0.247
201406 -0.175 100.560 -0.226
201409 -0.140 100.428 -0.181
201412 -0.128 99.070 -0.168
201503 -0.076 99.621 -0.099
201506 -0.061 100.684 -0.079
201509 -0.084 100.392 -0.109
201512 -0.055 99.792 -0.072
201603 -0.042 100.470 -0.054
201606 -0.056 101.688 -0.072
201609 -0.038 101.861 -0.048
201612 -0.005 101.863 -0.006
201703 -0.023 102.862 -0.029
201706 -0.014 103.349 -0.018
201709 0.000 104.136 0.000
201712 -0.022 104.011 -0.027
201803 -0.018 105.290 -0.022
201806 0.058 106.317 0.071
201809 0.063 106.507 0.077
201812 0.108 105.998 0.132
201903 0.149 107.251 0.180
201906 0.109 108.070 0.131
201909 0.080 108.329 0.096
201912 0.048 108.420 0.057
202003 0.020 108.902 0.024
202006 -0.015 108.767 -0.018
202009 0.050 109.815 0.059
202012 0.028 109.897 0.033
202103 0.000 111.754 0.000
202106 0.056 114.631 0.063
202109 0.019 115.734 0.021
202112 -0.006 117.630 -0.007
202203 -0.015 121.301 -0.016
202206 0.024 125.017 0.025
202209 0.008 125.227 0.008
202212 -0.005 125.222 -0.005
202303 -0.020 127.348 -0.020
202306 -0.032 128.729 -0.032
202309 -0.020 129.860 -0.020

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Nymox Pharmaceutical  (OTCPK:NYMXF) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Nymox Pharmaceutical was 229.33. The lowest was 229.33. And the median was 229.33.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Nymox Pharmaceutical Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Nymox Pharmaceutical's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Nymox Pharmaceutical (Nymox Pharmaceutical) Business Description

Traded in Other Exchanges
N/A
Address
Bay & Deveaux Streets, Nassau, BHS
Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.
Executives
James George Robinson director 10 EAST LEE STREET, SUITE 2705, BALTIMORE MD 21202
Erik Danielsen officer: Chief Financial Officer 9900 CAVENDISH BLVD, ST LAURENT A8 H4M 2V2
Paul Averback director, 10 percent owner, officer: CEO C/O NYMOX PHARMACEUTICAL CORPORATION, 9900 CAVENDISH BLVD., SUITE 306, ST. LAURENT A8 H4M 2V2
Randall J Lanham director, officer: General Counsel

Nymox Pharmaceutical (Nymox Pharmaceutical) Headlines

From GuruFocus

May 2023 Market Cap Requirement Update

By GlobeNewswire GlobeNewswire 11-25-2022

Nymox Shareholder Update

By GuruFocusNews GuruFocusNews 12-13-2021

May 2023 Market Cap Requirement Update

By Value_Insider Value_Insider 11-25-2022

Nymox Announces $2 Million Private Placement

By Marketwired 08-02-2023

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 05-23-2022

NYMOX Provides Current Update

By Marketwired Marketwired 10-11-2021

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 06-12-2022

NYMOX Appeals Deficiency Letter

By GlobeNewswire GlobeNewswire 01-06-2023

NYMOX Receives Deficiency Letter from NASDAQ

By PurpleRose PurpleRose 07-14-2022